Second generation S1P pathway modulators: research strategies and clinical developments.

@article{Bigaud2014SecondGS,
  title={Second generation S1P pathway modulators: research strategies and clinical developments.},
  author={Marc Bigaud and Danilo Guerini and Andreas Billich and Fr{\'e}d{\'e}ric Bassilana and Volker Brinkmann},
  journal={Biochimica et biophysica acta},
  year={2014},
  volume={1841 5},
  pages={745-58}
}
Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS) through demyelination and neurodegeneration. Until recently, major therapeutic treatments have relied on agents requiring injection delivery. In September 2010, fingolimod/FTY720 (Gilenya, Novartis) was approved as the first oral treatment for relapsing forms… CONTINUE READING